9995:HKEXRemeGen Co. Ltd. Class H Analysis

RemeGen (9995.HK) is trading at HK$88.8, comfortably above its 20‑day (≈HK$81.5) and 50‑day (≈HK$84.5) SMAs and near the identified resistance of HK$91.75, while the MACD shows a bullish crossover with a positive histogram. The forward PE of 62.6 dwarfs the industry average of 26, and the price‑to‑book ratio of 18.6 signals a premium valuation despite a solid operating margin of 78.6% and a ROE of 32.9%. Revenue growth remains modest at 2% YoY, and the company carries a high debt‑to‑equity ratio of 94%, though cash balances are sizable. Volatility is elevated at 56% over the past 30 days and beta hovers around 1, indicating sensitivity to market swings. The pipeline of ADCs and biologics offers upside potential, but the lack of dividend and a negative trailing EPS temper expectations. Analyst consensus is a “Buy” with a median target of HK$105.8, reflecting optimism on upcoming product launches. However, the high valuation and regulatory exposure in both China and the U.S. introduce notable risk. Liquidity appears adequate with increasing volume and a market cap of HK$52.9 bn. In the short term, price momentum and technical strength support a cautious buy stance, while medium‑term outlook is more balanced given valuation concerns. Over a longer horizon, the growth narrative may outweigh current pricing pressures, making the stock a potential buy for patient investors.